[Federal Register Volume 76, Number 36 (Wednesday, February 23, 2011)]
[Notices]
[Page 10038]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-3990]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Determination That a Demonstration Needle Exchange Program Would
be Effective in Reducing Drug Abuse and the Risk of Acquired Immune
Deficiency Syndrome Infection Among Intravenous Drug Users
AGENCY: Office of the Secretary, Department of Health and Human
Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Surgeon General of the United States Public Health
Service, VADM Regina Benjamin, M.D., M.B.A., has determined that a
demonstration needle exchange program (or more appropriately called
syringe services program or SSP) would be effective in reducing drug
abuse and the risk of infection with the etiologic agent for acquired
immune deficiency syndrome. This determination reflects the scientific
evidence supporting the important public health benefit of SSPs, and is
necessary to meet the statutory requirement permitting the expenditure
of Substance Abuse Prevention and Treatment (SAPT) Block Grant funds
for SSPs.
FOR FURTHER INFORMATION CONTACT: Substance Abuse and Mental Health
Services Administration (SAMHSA), 1 Choke Cherry Road, Rockville,
Maryland, attention John Campbell, 240-276-2891.
SUPPLEMENTARY INFORMATION: The U.S. Department of Health and Human
Services' Substance Abuse and Mental Health Services Administration
administers the SAPT Block Grant authorized in section 1921 of Title
XIX, Part B, Subpart II of the Public Health Service (PHS) Act (42
U.S.C. 300x-21). Section 1931(a)(1)(F) of Title XIX, Part B, Subpart II
of the PHS Act (42 U.S.C. 300x-31(a)(1)(F)) prohibits the expenditure
of SAPT Block Grant funds to ``* * * carry out any program prohibited
by section 256(b) of the Health Omnibus Programs Extension Act of
1988'' (42 U.S.C. 300ee-5). Section 256(b) prohibits the use of ``* * *
funds provided under this Act or an amendment made by this
Act[hellip]to provide individuals with hypodermic needles or syringes *
* * unless the Surgeon General of the Public Health Service determines
that a demonstration needle exchange program would be effective in
reducing drug abuse and the risk that the public will become infected
with the etiologic agent for acquired immune deficiency syndrome.''
SSPs are widely considered to be an effective way of reducing HIV
transmission among individuals who inject illicit drugs and there is
ample evidence that SSPs also promote entry and retention into
treatment (Hagan, McGough, Thiede, et al., 2000, Journal of Substance
Abuse Treatment, 19, 247-252). According to research that tracks
individuals in treatment over extended periods of time, most people who
get into and remain in treatment can reduce or stop using illegal or
dangerous drugs. In addition to promoting entry to treatment, there are
studies that document injection reductions for drug users who
participate in SSPs. Hagan, et al., found that, not only were new SSP
participants five times more likely to enter drug treatment than non-
SSP participants, former SSP participants were more likely to report
significant reduction in injection, to stop injecting altogether, and
to remain in drug treatment. A summary of the research on SSPs is
available at http://www.samhsa.gov/ssp.
The Surgeon General of the United States Public Health Service has
therefore determined that a demonstration syringe services program
would be effective in reducing drug abuse and the risk that the public
will become infected with the etiologic agent for acquired immune
deficiency syndrome. The Department of Health and Human Services plans
to issue guidelines regarding implementation requirements for SSPs
based on this determination.
Dated: February 17, 2011.
Kathleen Sebelius,
Secretary.
[FR Doc. 2011-3990 Filed 2-18-11; 4:15 pm]
BILLING CODE 4150-28-P